Form 4: Prelude Therapeutics Director David P. Bonita Acquires Stock Options

Director David P. Bonita acquired stock options in Prelude Therapeutics, with potential transfer obligations to OrbiMed Private Investments VI, LP.

Summary

• On June 14, 2024, David P. Bonita, a director of Prelude Therapeutics Inc., was granted stock options to purchase 23,500 shares of common stock at an exercise price of $3.90.
• The options vest fully upon the earlier of the next annual stockholder meeting or one year from the grant date, contingent on continued service to the Issuer.
• Bonita is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will then provide them to OrbiMed Private Investments VI, LP.

Sentiment

Score: 6

Explanation: The document describes a routine stock option grant, which is neutral to slightly positive as it aligns director incentives with shareholder value.

Positives

• The grant of stock options aligns the director's interests with those of the company and its shareholders.
• The vesting schedule incentivizes continued service to the company.

Risks

• The obligation to transfer securities or economic benefits to OrbiMed Private Investments VI, LP may reduce the director's direct financial incentive.

Future Outlook

The director's continued service to the company is contingent on the vesting of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially benefiting shareholders.
• The director's continued service is incentivized, potentially benefiting the company and its stakeholders.

Key Dates